| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Nifuroxazide (Bacifurane; Diafuryl; Ambatrol; Antinal; Diarlidan) is a potent, cell-permeable and orally bioavailable nitrofuran-based antidiarrheal agent that effectively suppresses the activation of cellular STAT1/3/5 transcription activity with IC50 of 3 μM against IL-6-induced STAT3 activation in U3A cells. It is a nitrofuran antibiotic that has been approved for treating colitis and diarrhea. Nifuroxazide is described to block constitutive phosphorylation of STAT3 by reducing Jak kinase autophosphorylation, decreasing the viability of myeloma cells depending on constitutive STAT3 activity for survival while not affecting normal peripheral blood mononuclear cells.
| ln Vitro |
Nifuroxazide treatment of U266 cells results in a notable dose-dependent reduction in STAT3 tyrosine phosphorylation. As early as one hour after therapy, STAT3 tyrosine phosphorylation is rapidly inhibited, and this suppression lasts for at least twenty-four hours. Nifuroxazide treatment of U266 or INA6 cells for 48 hours causes a dose-dependent decrease of cell viability in both cell types, with an EC50 of roughly 4.5 μM. Notably, nifuroxazide has no harmful effect on MM cells that lack constitutive STAT3 activation[1].
|
||
|---|---|---|---|
| ln Vivo |
Treatment with Nifuroxazide could, in a dose-dependent way, suppress tumor growth and weight in comparison to the vehicle group, with the inhibition rate of tumor volumes being 43.0% and 62.1% at 25 mg/kg and 50 mg/kg, respectively. Additionally, it has been demonstrated that nifuroxazide causes cleaved caspase-3-positive cells to undergo apoptosis and dramatically reduces the growth of nuclear Ki-67-positive cells. Furthermore, it has been discovered that nifuroxazide therapy may suppress the expression of p-Stat3, MMP-2, and MMP-9 in A375 tumor tissues. Additionally, Nifuroxazide prevents MDSC penetration into the lung, which may be linked to the B16-F10 melanoma metastatic model's reduction of tumor cell distant colonization[2].
|
||
| Animal Protocol |
|
||
| References | |||
| Additional Infomation |
Nifuroxazide is a member of benzoic acids.
|
| Molecular Formula |
C12H9N3O5
|
|
|---|---|---|
| Molecular Weight |
275.22
|
|
| Exact Mass |
275.054
|
|
| CAS # |
965-52-6
|
|
| Related CAS # |
|
|
| PubChem CID |
5337997
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.5±0.1 g/cm3
|
|
| Melting Point |
281-283°C
|
|
| Index of Refraction |
1.653
|
|
| LogP |
0.59
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
20
|
|
| Complexity |
387
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
C1=CC(=CC=C1C(=O)N/N=C/C2=CC=C(O2)[N+](=O)[O-])O
|
|
| InChi Key |
YCWSUKQGVSGXJO-NTUHNPAUSA-N
|
|
| InChi Code |
InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17)/b13-7+
|
|
| Chemical Name |
4-Hydroxy-N-[(E)-(5-nitrofuran-2-yl)methylideneamino]benzamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.58 mg/mL (9.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.58 mg/mL (9.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6335 mL | 18.1673 mL | 36.3346 mL | |
| 5 mM | 0.7267 mL | 3.6335 mL | 7.2669 mL | |
| 10 mM | 0.3633 mL | 1.8167 mL | 3.6335 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
